{"schema_version":"1","generated_at":"2026-11-22T00:37:50.523Z","data_as_of":null,"url":"https://www.findmykol.com/kol/david-biggs","json_url":"https://www.findmykol.com/kol/david-biggs/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"david-biggs","name":"David Biggs","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Frisco","state":"CO","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"David Biggs is an Oncology physician. OpenAlex indexes 24 publications with 1,500 citations (h-index 11).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":24,"cited_by_count":1500,"h_index":11,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":20,"program_years":{"first":2021,"last":null},"rows_total":25,"shown":3,"withheld":22,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":25.57,"payment_count":1},{"payer":"Merck Sharp & Dohme LLC","program_year":2024,"amount_usd":25.12,"payment_count":1},{"payer":"Pharmacyclics LLC, An AbbVie Company","program_year":2023,"amount_usd":56.42,"payment_count":2}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":3,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":47.3,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":47.3,"drugs":[{"name":"Eliquis","share_pct":58.1},{"name":"Xarelto","share_pct":41.9}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":38.5,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":38.5,"drugs":[{"name":"Anastrozole","share_pct":100}],"max_beneficiaries":13}]},{"area":"Other","share_pct":14.3,"classes_total":1,"classes":[{"class":"Iron Chelator","setting":"prescribed","share_pct":14.3,"drugs":[{"name":"Deferasirox","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":24,"shown":5,"withheld":19,"matched_by":"OpenAlex author record","recent":[{"title":"SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.","year":2019,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps1110","status":"verified"},{"title":"Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101","year":2018,"journal":"The Oncologist","source_url":"https://doi.org/10.1634/theoncologist.2018-0298","status":"verified"},{"title":"The Role of Heart-Related Dose-Volume Metrics on Overall Survival in the RTOG 0617 Clinical Trial","year":2018,"journal":"International Journal of Radiation Oncology*Biology*Physics","source_url":"https://doi.org/10.1016/j.ijrobp.2018.06.247","status":"verified"},{"title":"Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer","year":2018,"journal":"Cancer Medicine","source_url":"https://doi.org/10.1002/cam4.1569","status":"verified"},{"title":"Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials","year":2017,"journal":"JAMA Oncology","source_url":"https://doi.org/10.1001/jamaoncol.2016.6749","status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":22,"publications":19}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}